Kornimate/medical-research-clean huggingface dataset:
an exploratory study of perioperative venous access in obese patients

Conditions: Catheter Complications

Summary: this study is intended to explore the application effect of long peripheral intravenous catheters(lpcs) and midline catheters(mcs) in the perioperative period of obese patients, aiming at providing the scientific basis for the optimal perioperative venous access for the obese patients.

this study is intended to explore the application effect of long peripheral intravenous catheters(lpcs) and midline catheters(mcs) in the perioperative period of obese patients; at the same time, the lpcs will be used as the control group and the mcs as the experimental group, to compare whether the application of lpcs in the perioperative period of obese patients is not inferior to that of the mcs; the comprehensive comparison of the effect of the clinical application and the evaluation of the health economics, aiming at providing the scientific basis for the optimal perioperative venous access for the obese patients.

Eligibility criteria:
inclusion criteria: * obese patients (bmi ≥ 30kg/m2) who are to undergo surgery. * expected length of hospitalisation within 2 weeks. * conscious and able to communicate normally. exclusion criteria: * it is expected that perioperative medications will need to be infused via a central venous catheter (e.g. total parenteral nutrition tpn); * patients with an indwelling central venous catheter on admission
single dosing clinical trial of hl151

Conditions: Rhinitis, Allergic, Perennial

Summary: the purpose of this study is to assess the pharmacokinetic characteristics of bepotastine after single oral administration of talion tab, a ir formulation of bepotastine as reference drug and hl151, a sr formulation of bepotastine as test drug in healthy male adults. additionally the safety and tolerability of two drugs will be evaluated.


Eligibility criteria:
inclusion criteria: 1. healthy male volunteer in the age of 19-45 2. body weight≥50kg and bmi 18\~29 kg/m2 3. subject who sign on an informed consent form willingly exclusion criteria: 1. subject with serious active cardiovascular, respiratory, hepatologic, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease 2. subject with acute disease within 28 days prior to study medication dosing 3. subject with known for history of disease which affect on the absorption, distribution, metabolism, excretion of drug 4. subject with clinically significant chronic disease 5. positive on the test of hbs ag, anti-hcv ab, anti-hiv ab, vdrl 6. use of any prescription medication within 14 days prior to study medication dosing 7. use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing 8. subject with clinically significant allergic disease 9. subject with known for hypersensitivity reaction to bepotastine 10. subject with any of the following conditions in laboratory test * ast/alt \> unl (upper normal limit) x 2 * total bilirubin \> unl x 2 * renal failure with clcr \< 50ml/min calculated on cockcroft-gault \[cockcroft-gault gfr = (140-age) \* (wt in kg) / (72 \*cr)\] * sbp\<100mmhg or ≥160mmhg, dbp\<60mmhg or ≥100mmhg * qtc\>440msec on ecg * serum potassium \ 5.5 meq/l 11. immunological incompetence, immune deficiency or taking immunosuppressants 12. subject who cannot take standard meal 13. subject with whole blood donation within 60days, component blood donation within 20days prior to study medication dosing 14. subject with blood transfusion within 30days prior to study medication dosing 15. participation in any clinical investigation within 90days prior to study medication dosing 16. continued excessive use of caffeine (caffeine \>five cups/day), alcohol(alcohol\>30g/day) and severe heavy smoker(cigarette \>10 cigarettes per day) 17. subject with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator 18. subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within 30days prior to study medication dosing 19. subject who are not using adequate means of contraception 20. subject with genetic problems such as galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption 21. subject with history of drug abuse or drug addiction
immunotep with 68-ga in metastatic colo rectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: evaluation of the sensitivity of the immuno-pet pet / ct pretargeted with the bispecific anti-cea x anti-hsg tf2 antibody and imp-288 peptide labeled with gallium-68 for imaging potential candidate patients for surgery of local resection of one or more metastases at diagnosis or during relapse ccr expressing cea.

injection of a bispecific anti-cea x anti-hsg antibody tf2 (120 nmoles) and 30 hours later imp-288 peptide labeled with gallium-68 (3 to 6 nmoles/150 mbq). a tep imaging acquisition is plannified 60 min after the 68-ga injection.

Eligibility criteria:
inclusion criteria: * existence of one or more metastases of of colorectal cancer (crc) expressing the cea , potentially accessible by surgical or thermo resection at the moment of the diagnosis or at relapse. or * isolated and progressive elevation of plasma cea during the monitoring of crc with high metastatic risk * more than 18 years * negative pregnancy test for women of childbearing age. women of childbearing age should take effective continuous contraception for 3 months. * at least 4 weeks after the last treatment and after recovery of potential toxicity * karnofsky more than 70 or ecog 0-1 * life expectancy of at least 6 months * cea positive immunohistochemistry or plasma cea supperior or equal to the normal level * creatinin less or equal 200 micromol/l * signed informed consent * geographical proximity exclusion criteria: * pregnancy or breastfeeding * serious illness or comorbidity assessed risk * history of other cancer within 5 years, with the exception of skin carcinomas other than melanomas or in-situ carcinoma of the cervix * anti-antibody presence in patients who have already received antibody * hypersensitivity to antibodies or proteins * intellectual inability to sign the informed consent * insulin-dependent diabetic patient or non-insulin dependent
an intervention program to reduce to the risk of persistent symptoms after concussion

Conditions: Mild Traumatic Brain Injury

Summary: this study investigates how well a new therapy program prevents persistent symptoms (e.g., headaches, fatigue, irritability, etc.) after concussion. the program involves examining beliefs about concussion and learning healthy coping strategies, and is completed with the first three months post-injury.

although the majority of patients with mild traumatic brain injury (mtbi) experience complete recovery within three months, a sizeable group continues to report frequent and severe symptoms such as headaches, fatigue, difficulty concentrating, forgetfulness, and irritability, in what is labeled persistent post-concussion syndrome (pcs). persistent pcs is associated with vocational, recreational, and social disability. early education and reassurance (treatment as usual) is effective in general, but appears insufficient for this subgroup. recent research has identified risk factors for persistent pcs, including inaccurate illness beliefs, maladaptive coping behaviour, and emotional distress. the present study will evaluate the additive efficacy of a cognitive-behavioural therapy protocol designed to modify these risk factors, over and above treatment as usual. participants with mtbi will be recruited within six weeks of injury. those identified as being at-risk for persistent pcs based on evidence-based criteria will receive treatment as usual and then be randomly assigned to receive either no further intervention or cognitive-behavioural therapy. we hypothesize that the group receiving cognitive-behavioural therapy will have fewer pcs symptoms and be less disabled at follow-up. we also hypothesize that compensation-seeking status will mitigate this improvement and that illness beliefs, coping behaviour, and emotional distress will mediate this improvement. a blinded rater will conduct the baseline and outcome assessments.

Eligibility criteria:
inclusion criteria: * incurred head trauma within six weeks of study entry * meet american congress of rehabilitation criteria for mtbi, documented by the referring/treating physician * subjective report at least one symptom attributable to head trauma * english as preferred language for communication * considered at-risk for persistent pcs based on prognostic model from whittaker et al. (2007) exclusion criteria: * medical documentation of skull fracture or acute intracranial abnormality on neuroimaging, consistent with "mild-complicated" tbi * self-reported history of a neurological disorder (including prior mtbi within the past six months)

Keywords: mild traumatic brain injury concussion post-concussion syndrome cognitive-behavioural therapy
implementation of a pediatric-to-adult asthma transition program

Conditions: Asthma; Education

Summary: despite the clear and often stated need, a formal transition program does not exist for asthma patients as they move from pediatric to adult care in western canada. this population is not having their health care needs met. the investigators proposed study would evaluate a well structured transition program designed to facilitate continuity of care for this at risk patient population. primary hypothesis: a pediatric-to-adult asthma transition program will improve the asthma-specific quality of life of young asthma patients in the calgary area over a 1 year period. secondary hypothesis: a pediatric-to-adult asthma transition program will improve asthma control, decrease asthma exacerbations, and reduce health care utilization in young asthma patients in the calgary area over a 1 year period.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of asthma (as confirmed by a pediatric respirologist or pediatrician with asthma expertise, and including evidence of variable airflow obstruction, bronchial hyperresponsiveness, airway inflammation, and/or response to therapy) exclusion criteria: * patients who are known to be non-adherent within the calgary regional pediatric asthma clinic (defined as \>50% missed appointments over a 2 year period) * patients unable to complete pulmonary function testing * patients with a history of significant respiratory comorbid conditions (including history of cystic fibrosis, alpha-1 antitrypsin deficiency, and lung transplant - rhinosinusitis patients will not be excluded) * patients unable to provide consent.

Keywords: asthma transition program pediatric adult
the efficacy of protein supplementation on attenuating muscle atrophy following disuse in the collegiate population

Conditions: Disuse Atrophy

Summary: following orthopedic surgery and/or injury, a significant loss of muscle mass is generally observed. while this loss of muscle mass appears to be the norm, it causes significant problems in both the athletic and general population. athletes struggle to regain their performance because of the decrease in muscle mass and also have a greater potential for reinjury while they are in a depleted state. in the general population, and particularly among the elderly, this loss in muscle mass can be even more devastating because as people age, it is more difficult to regain muscle after it is lost. in elderly individuals, this loss in muscle mass can lead to significant disability, diminished quality of life along with an increased risk of falls. in addition to the muscle mass lost during the post-operative period, the strength of the muscle also decreases. this has obvious performance implications in athletes, as well as having the potential to extend recovery time. in the elderly, decreased strength may result in reduced independence and inability to perform activities of daily living. many previous bed rest studies have reported that significant bone loss also occurs during times of decreased mechanical loading. the post-operative period generally results in decreased mechanical loading; however, some muscle loading will still occur during the rehabilitation process. the dynamic relation between muscle activity/loading and bone density changes in the post-operative state has not been fully described and requires further study. with this knowledge of the importance of nutrition to the musculoskeletal system, applying the principles of increased protein intake through the addition of a dietary supplement to a population preparing for orthopedic surgery and subsequent muscle disuse is a logical next step. the investigators hypothesize that through the consumption of a protein-based dietary supplement three times per day (75g protein), along with educating patients on the importance of consuming foods that are high in protein, there will be an attenuation of decreases in muscle mass and strength as well as losses in bone that occur with orthopedic injury and disuse. the investigators long-term goal is to identify a nutritional protocol that can be implemented prior to and following orthopedic surgery to diminish the deleterious effects of the subsequent disuse on muscle and bone.


Eligibility criteria:
inclusion criteria: * participants will be physically active males and females aged 18-25 with no history of a lower extremity injury 12 months prior to participation. physically active will be classified as participating in physical activity for at least 3 minutes and a minimum of 3 days per week. exclusion criteria: * participants will be excluded if they are participating in any other research projects that could potentially affect the outcomes of this study.
analysis the positive rate of tumor markers among physical examination population

Conditions: Tumor

Summary: to analyze the positive rate of tumor markers (tm) among health examination population in a tertiary grade a class hospital, compare the differences between different age and sex groups, and explore the possible influencing factors of tm positive.

from january 2019 to december 2019, who underwent physical examination in peking university third hospital were included in the study. the expression levels of carcinoembryonic antigen (cea),α-fetoprotein (afp), carbohydrate antigen 19-9 (ca 19-9), carbohydrate antigen-125 (ca-125), carbohydrate antigen 72-4(ca 72-4), carbohydrate antigen 15-3 (ca 15-3), carbohydrate antigen 242(ca 242), squamous cell carcinoma antigen（scc）, cyfra21-1, total prostate-specific antigen (tpsa ) , free prostate-specific antigen(fpsa), neuron specific enolase(nse) were detected by electro chemistry luminescence method. the positive rates of tm were analyzed by descriptive statistical method explore. the differences between different age and sex groups and the influencing factors were explored by statistic by inferential statistical method.

Eligibility criteria:
inclusion criteria: * those who have taken a physical examination and performed at least one tm test exclusion criteria: * basic information is missing and cannot be retrieved * the patient was diagnosed with malignant tumor before examination * those who have not done any tm tests

Keywords: physical examination population tumor marker tm
smas: a prospective study in a single institution

Conditions: Superior Mesenteric Artery Syndrome

Summary: superior mesenteric artery syndrome (smas) is a rare cause of duodenal obstruction, that should be suspected in cases of chronic, refractory upper digestive symptoms. between 2008 and 2016, 39 consecutive patients with chronic gastrointestinal symptoms and a diagnosis of smas were prospectively included in the study, in order to describe their demographic, clinical and outcome features. all patients underwent duodenojejunostomy.


Eligibility criteria:
inclusion criteria (at least 2 of the following): * severe and frequent upper digestive symptoms (occurring at least once a week), associated to poor quality of life and refractory response to medical treatment; * a condition of underweight (bmi \<18.5 kg/m2) associated with difficulty eating; * severe complications of smas (e.g. gastric perforation, acute pancreatitis, aspiration pneumonia); * suggestive findings of smas at barium swallow; * diagnostic aortomesenteric angle and distance at ct/mr angiography. exclusion criteria: * inability to provide the informed consent; * malignancies; * bowel motility disorders; * severe psychiatric illness; * pregnancy; * impossibility to perform the required diagnostic workup.

Keywords: superior mesenteric artery syndrome chronic duodenal obstruction duodenojejunostomy wilkie's syndrome
a randomized, open label, single dose, 2-way cross-over clinical trial to compare the safety and pharmacokinetic characteristics of exforge® and g-0081 in healthy male volunteers

Conditions: Healthy Male Volunteer

Summary: study design : randomized, open label, single-dose, 2-way cross-over design phase : phase i


Eligibility criteria:
inclusion criteria: * healthy male volunteers between the ages of 20 to 50 years old within the range of ±20% of ibw(ideal body weight) * having neither congenital/chronic diseases nor pathological symptoms/findings as results of medical examination * doctor determines to be suitable as subjects within 4 weeks ago before administration exclusion criteria: * hypersensitivity(or history of hypersensitivity) to amlodipine and valsartan * active liver diseases or exceed 1.5 times the normal range of ast, alt * gastrointestinal diseases or surgeries that affect absorption of drug * excessive drinking(exceed 30g/week) and excessive caffeine(exceed 250mg/day) * smoking over 10 cigarettes per day
efficacy and safety of modified gegen qinlian decoction for ulcerative colitis with damp-heat syndrome

Conditions: Ulcerative Colitis

Summary: ulcerative colitis(uc) seriously affect the quality of life in patients. clinically, it is effective to apply therapeutic method of clearing heat and promoting diuresis to the common syndrome of dampness-heat. dysbiosis of intestinal microbiota is closely related to the immune imbalance and intestinal mucosal barrier injury. c1orf106/cyth-1/arf6 signal pathway, which derive from intestinal micro environment changes,is the mainly cause of intestinal mucosal barrier injury, and this is may be the common pathogenesis of dampness-heat syndrome in uc . based on the clinic, the project is to study the effect and mechanism of chinese compound formula of clearing heat and promoting dieresis in modulating intestinal microbiota dysbiosis, repairing intestinal mucosal barrier and reconstructing intestinal microenvironment. with the combination of metagenomics and metabonomics, the study compare the differences of co-metabolites of intestinal microbiota and host within the healthy people, uc patients with dampness-heat syndrome, to explore the relevance between intestinal flora and host co-metabolites. furthermore, the experimental study is to clarify the drug targets via c1orf106/ cyth-1/arf6 signal pathway.through the study of association between dampness-heat syndrome in uc and intestinal microbiota, it is of important academic significance to reveal the chinese theory intension of "homotherapy for heteropathy ".


Eligibility criteria:
inclusion criteria: * (1) it meets the diagnostic criteria of uc (left semi-colon type, active period, mild) and meets the diagnostic criteria for damp-heat syndrome. (2) age between 18 and 70 years old. (3) not taking antibiotics, steroids and other hormones, chinese herbal preparations in the past week (including) probiotics such as oral and intravenous), microecological preparations or yogurt. (4) the subject informed and voluntarily signed the informed consent form. ; (5) have a certain reading ability exclusion criteria: * (1) patients with severe organ, liver, kidney and other major organ diseases, hematopoietic system, nervous system or mental illness; (2) combined with other digestive systemic lesions (such as peptic ulcer), or systemic diseases affecting digestive tract motility (eg hyperthyroidism, diabetes); (3) those who are or need to continue to use drugs that may affect gastrointestinal function (antidiarrheals, antidepressants, anxiolytics, intestinal flora regulators, antibiotics, etc.); (4) those with a history of allergic reactions to related drugs and a history of severe food allergies.
chronic effects of natural and interesterified fats margarine on insulin sensitivity and selected markers of cardiovascular diseases (cvd)

Conditions: Overweight

Summary: the investigators hypothesized that there will be a significant difference between the effects of trans-free palm-, interesterified palm- and interesterified soybean oil blend on cardiovascular disease, inflammation, insulin resistance and obesity.

human volunteers will be conditioned for a 8 wk intervention on 3 different test diets providing 30 % energy as fat, 15% energy as protein and 55% energy as carbohydrate according to parallel designed sequences. the test fats used for this study are palm oil, chemically interesterified palm oil and chemically interesterified fully hydrogenated soybean oil and soft oil blend in the form of margarine. volunteers will be restricted to follow the dietary guidelines throughout the study. blood collection sessions will held before and after every diet intervention. outcome measures of the study are serum lipid profile, markers of inflammation, markers of obesity and insulin resistance.

Eligibility criteria:
inclusion criteria: * adult males and females, aged 20-60 yr * staff and students of international medical university, imu/ staff of malaysian palm oil board, mpob to facilitate centralized consumption of the test fats/snacks * bmi 21 - 30 kg/m2 exclusion criteria: * abnomal liver function test (elevated transaminases- alanine aminotransferase,alt; aspartate aminotransferase,ast))/ abnormal kidney function test (elevated plasma creatinine) * history of type 2 diabetes mellitus, cancer, stomach ulcers, drug abuse or alcoholism * smokers * on lipid/blood pressure- lowering medication/supplements * blood pressure\>140/90 mmhg * fasting total cholesterol \> 6.5 mmol/l * fasting tag \> 2.0 mmol/l * candidates who are going abroad during the planned schedule for the dietary intervention